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Abstract
Pulmonary surfactant protein D (SP-D) is a host defence lectin of the innate immune system that enhances clearance of
pathogens and modulates inflammatory responses. Recently it has been found that systemic SP-D is associated with
metabolic disturbances and that SP-D deficient mice are mildly obese. However, the mechanism behind SP-D’s role in
energy metabolism is not known. Here we report that SP-D deficient mice had significantly higher ad libitum energy intake
compared to wild-type mice and unchanged energy expenditure. This resulted in accumulation but also redistribution of fat
tissue. Blood pressure was unchanged. The change in energy intake was unrelated to the basal levels of hypothalamic Pro-
opiomelanocortin (POMC) and Agouti-related peptide (AgRP) gene expression. Neither short time systemic, nor
intracereberoventricular SP-D treatment altered the hypothalamic signalling or body weight accumulation. In ad libitum
fed animals, serum leptin, insulin, and glucose were significantly increased in mice deficient in SP-D, and indicative of insulin
resistance. However, restricted diets eliminated all metabolic differences except the distribution of body fat. SP-D deficiency
was further associated with elevated levels of systemic bacterial lipopolysaccharide. In conclusion, our findings suggest that
lack of SP-D mediates modulation of food intake not directly involving hypothalamic regulatory pathways. The resulting
accumulation of adipose tissue was associated with insulin resistance. The data suggest SP-D as a regulator of energy intake
and body composition and an inhibitor of metabolic endotoxemia. SP-D may play a causal role at the crossroads of
inflammation, obesity, and insulin resistance.
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Introduction
SP-D is an innate host defense lectin and widely used as
seromarker of pulmonary integrity [1]. SP-D can be measured in
serum by specific assays [2,3] and appears to be increased early in
the course of lung injury, and the elevated concentrations are
mainly thought to reflect pulmonary epithelial injury [1,4]. SP-D
synthesis is located to the alveolar lining, but in addition the
protein is expressed in endothelial cells, various epithelial linings
including the gastrointestinal tract and the brain [5,6,7].
Systemic SP-D was recently demonstrated to be decreased in
type II diabetes, positively associated with insulin sensitivity after
oral glucose tolerance test [8] and negatively associated with
obesity [9,10]. In contrast, high serum SP-D levels were recently
associated with cardiovascular disease (CVD) and total mortality
in patients with documented coronary artery disease, independent
of other well-established risk factors eg. age, sex, and cigarette
smoking. SP-D was reported more discriminative of CVD and
total mortality than any of these factors except for age [11].
The nature of the relation between SP-D and metabolic
disturbances is unknown. Abnormalities in pulmonary function are
considered as risk factors for development of type 2 diabetes [12].
In addition, inflammatory responses in the lung influence
adipocyte production of leptin and adiponectin. On the other
hand, overweight and obesity are considered to be significant risk
factors for pulmonary disease and respiratory symptoms [13,14].
The underlying mechanisms whereby the pulmonary system may
affect metabolism are diverse [13] and involve altered levels of
several innate immune receptors [15] besides SP-D, but exact
direction of the association between reduced lung function and
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metabolism, as well as the pathophysiological mechanisms, have
not been established.
SP-D’s role in innate immunity is to enhance phagocytosis of
microorganisms [16] and to directly inhibit growth of pathogens
by increasing membrane permeability [17]. SP-D is further known
to bind gram-negative bacterial lipopolysaccharide directly and
may thus take part in the scavenging of the endotoxin [18]. SP-D
also down-regulates bacterial endotoxin-elicited inflammatory
responses in alveolar macrophages by high-affinity binding to
the Toll-like receptor 4 (TLR4) and MD-2 complex [19]. The
importance of SP-D in antimicrobial and inflammatory responses
has been determined using Spd2/2 mice [20].
Unchallenged Spd2/2 mice develop pulmonary emphysema
and alveolar phospholipid accumulation at a young age in addition
to chronic pulmonary inflammation associated with increased
metalloproteinase activity, NF-kB activation, and macrophage
oxidant production [21,22]. In humans and mice, the presence of
pulmonary emphysema is usually associated with progressive loss
of tissue involving fat mass and fat-free mass, respiratory cachexia
secondary to elevation of inflammatory cytokine levels, and the
reduction of anabolic hormone levels [23,24,25]. However, despite
the deranged pulmonary phenotype, the SP-D deficient mice
appear mildly obese [9]. Systemic lipid homeostasis is also
influenced by SP-D deficiency, as it causes elevated plasma
triglycerides and high-density lipoprotein cholesterol (HDL-C);
diet-induced formation of atherosclerotic lesions is depressed in
Spd2/2 mice [26]. Recently, it was demonstrated that SP-D
expression is significantly increased in pancreatic b-cells under
conditions of pregnancy-induced insulin resistance and in newly
formed b-cells making the molecule a specific marker for new
insulin producing cells [27,28]. Together these observations
suggest that SP-D may have functions, which affect the energy
metabolism in addition to the well-known immune functions.
Obesity and metabolic disturbances may be evoked by or
influenced by a multitude of different stimuli eg. energy intake,
energy expenditure, central appetite regulation, modulation of
adipocyte function, and metabolic endotoxemia. Energy intake is a
major contributor and is regulated by a complex network
involving hypothalamic as well as extrahypothalamic structures
in the brain. The neuronal networks are associated with both
orexigenic and anorexigenic signals, of which POMC and AGRP
play central roles in the hypothalamic regulation of appetite and
food intake [29]. Extrahypothalamic pathways involved in the
regulation of energy intake, hedonic eating, and the role of leptin
herein are recognized, but not well described [30]. Adipose tissue
is dynamically linked with the immune system; indeed, the activity
of macrophage cells has a key role in adipocyte function and
increased abundance of macrophages is found in adipose tissue
[31,32]. Adipose tissue macrophages are thus suggested to be an
important factor for systemic insulin sensitivity [33]. Obese and
diabetic mice have been reported to display enhanced intestinal
permeability, which may result in increased systemic endotoxin
derived from gut microbiota. On the other hand, bacterial
endotoxin may trigger and maintain a low-tone continuous
inflammatory state and in this way metabolic endotoxemia has
been suggested to evoke obesity and insulin resistance in mice [34].
In addition to the pulmonary epithelium, other tissues have
been found to synthesize SP-D, notably the brain, metabolic
organs like the insulin producing pancreas, the gut, and the
endothelium throughout the body. The widespread distribution
justifies speculations about the ways by which SP-D may affect
metabolism. The present study set out to explore a set of different
metabolic variables, which could be affected by SP-D deficiency
and cause mild obesity. Initially, the body mass development of the
SP-D deficient mouse was compared to the corresponding wild-
type body mass during ad libitum energy intakes and fixed energy
intakes. In addition, the effects of recombinant SP-D administra-
tion on c-fos and neuropeptide gene expression within hypothal-
amus and body weight were investigated. We further performed
measurements of body composition, blood glucose, insulin and
leptin, measured blood pressure, estimated the adipocyte and
macrophage composition in fad pads, and measured basal systemic
endotoxin levels. The variables were analyzed in the SP-D
deficient mice in order to identify metabolism-related pathways
involved in the overall changes in body weight and body
composition. The major findings from the investigations include
hyperphagia, redistribution of body fat, insulin resistance, and
increased systemic bacterial endotoxin levels, indicative of
propensity for metabolic endotoxemia associated to SP-D
deficiency.
Materials and Methods
Longitudinal studies of body weight
SP-D deficient mice (Spd2/2) on a CD-1 background were
backcrossed in excess of 12 times with the C57BL/6N strain
(Charles River Laboratories, Sulzfeld, Germany). Male Spd2/2
and wild-type mice were fed ad libitum or with a fixed energy
value of 80% or 95% of wildtype ad libitum energy intake. Mice
were fed with a low fat diet (16.50 kJ/g; 59.3% (w/w)
carbohydrate; 16.5% protein; 7% fat; (AIN-93G (829051); Special
Diets Services, Witham, Essex, UK) or a high fat diet (19.90 KJ/g;
39.0% carbohydrate; 19.7% protein; 23.1% fat; (824116; Special
Diets Services, Witham, Essex, UK)). The two diets were
isoenergetically exchanged. This means that the composition of
all ingredients (vitamins and protein etc.) were equal per energy
unit, except from corn starch and fat. Diets were provided as
powder in a stainless steel feeder to minimize spillage. Mice were
housed individually in macrolon type II cages, except that mice fed
95% of normal energy intake were housed 6 to a macrolon type III
cage. Cages contained aspen woodchip bedding (Tapvei, Bro-
gaarden, Gentofte, Denmark) and nesting material (EnviroDri,
Brogarden, Gentofte, Denmark). The environment was controlled
with respect to temperature (21–24uC) and illumination (12 hour
light/dark cycle with a 30 min sunset and dawn function). All mice
had free access to water. Dietary treatment was initiated at 7 weeks
of age. Body mass was recorded regularly and ad libitum energy
intake was obtained over a period of 18 weeks. Venous blood
samples were collected by puncture of the retroorbital plexus
before initiation of the experiment and at the 9th and 18th week of
diet treatment. Sampling was preceded by a 6 hour fast from 0700
to 1300. At experiment termination the mice were sacrificed by
CO2 asphyxiation. The gonadal, retroperitoneal, and subcutane-
ous inguinal fat pads were subsequently dissected and weighed. All
animal experimental protocols were performed under a license
obtained from The national Animal Experiments Inspectorate
who also approved the study.
Serum glucose and free fatty acids
Serum glucose and free fatty acids were measured using a Cobas
Mira analyzer (Roche diagnostics). Glucose was analyzed using the
ABX Pentra Glucose HK CP kit (ABX diagnostics, Montpellier,
France), and serum free fatty acids were analyzed with the NEFA-
C kit (Wako Chemicals GmbH, Neuss, Germany). Assays were
performed according to manufactures directions.
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Measurement of adiponection, insulin and leptin
A Luminex 100 IS (Luminex corp., Austin, TX, USA) was
employed for measurement of adiponectin using the mouse single
plex adiponectin lincoplex kit (MADPK-71K-ADPN, Linco
Research Inc, St. Charles, Missouri, USA), and of insulin and
leptin using the mouse serum adipokine lincoplex kit (MADPK-
71K, Linco Research, St. Charles, Missouri, USA). More than 50
events were acquired per bead set. Assays were performed
according to manufactures directions. Data analysis was per-
formed using the StarStation ver. 2.0 software (Applied Cytometry
Systems, Sheffield, UK).
Measurements of energy, protein, and fat contents
Urine and faeces were collected over a four day period in
metabolic cages concomitant with recording of water and food
consumption. Urine was collected in 300 mL 1 M sulphuric acid,
while residual urine on the collective tract was collected with 1%
citric acid. Weight of urine, collected citric acid and faeces was
recorded and frozen at 220uC for subsequent analysis.
Total nitrogen content in urine, carcass and diets was analyzed
by the Kjeldahl method. Nitrogen release was facilitated by
destruction at 420uC in phosphoric acid and with cupper sulphate
as a catalyst (Kjeltab CK, Foss A/S, Hillerød, Denmark). Released
nitrogen was extracted using the Kjeltec auto distillation unit (Foss
A/S, Hillerød, Denmark). Nitrogen content was determined by
titration with HCl. Protein content was estimated from nitrogen
content by the conversion factor 6.25.
Energy content of urine, faeces and diets were determined using
the IKA calorimeter C 5000 Control (Ika Werke GmbH & Co.
KG, Staufen, Germany) by combustion in 100% oxygen at a
pressure of 30 bar. Samples were homogenized and dried in a
vacuum oven at 120uC before analysis.
Fat content of carcasses and diets were determined by liberation
of chemically bound fatty acids by HCl hydrolysis using the
hydrolysis unit SoxCap 2047 (Foss A/S, Hillerød, Denmark),
followed by ether-extraction using the Soxtec2050 extraction unit
(Foss A/S, Hillerød Denmark). The extracted lipid content was
dried and weighed.
Assimilated energy intake was determined as gross energy intake
subtracted by energy lost in faeces, and metabolizable energy
intake was determined as gross energy intake subtracted by energy
lost in faeces and urine.
Indirect calorimetry
The gas exchange was measured in an open-air-circuit
respiration unit (Micro-Oxymax calorimeter, Columbus Instru-
ments, Columbus, Ohio, USA). The unit contained four small
chambers with a volume of 2.0 L, in which the temperature was
kept approximately constant at 22–24uC. The oxygen consump-
tion was measured according to the paramagnetic principle and
the carbon dioxide production in accordance with the infrared
principle. Prior to each measurement, the gas sensors were
calibrated against a gas mixture of known concentration and
outdoor air.
Animals were placed individually in respiration chambers and
gas exchange was measured for 22 hours at an inflow of ambient
air into the chambers of 0.3 L/min. Ambient air and mixed cage
air were sampled for 1 min, both preceded by 4 min of purging to
allow sensors to adjust, for a total time of 10 min per chamber.
The actual data from each chamber were recalculated to standard
conditions (STP: temperature 0uC, pressure 760 mm Hg). Body
core temperature was measured using a rectal probe prior to gas
exchange measurements.
Energy expenditure (EE) was calculated from O2 consumption,
CO2 production and nitrogen content in urine (UN) in accordance
with Brouwer [35] and oxidation of carbohydrate (OXCHO) and
fat (OXF) [36].
EE, kJ = 16.186O2, ml+5.026CO2, ml25.996UN, mg
OXCHO, kJ = (22.9686O2, ml+4.1746CO2, ml
22.4466UN, mg)617.58
OXF, kJ = (1.7196O2, ml21.7196CO2, ml21.9636UN,
mg)639.76
Measurements of blood pressure in conscious mice
Male and female Spd2/2 and wild-type mice 8–9 months of
age were used for invasive measurements of mean arterial pressure
(MAP). Male Spd2/2 and wild-type mice 10–11 months of age
were used for MAP measurements after NG-nitro-L-arginine
methyl ester (L-NAME) infusion (n = 4–6 per treatment group).
Animals were anaesthetized with ketamine hydrochloride and
xylazine (50 mg/kg and 10 mg/kg, IP). The anaesthesized mice
were pinched between the toes in order to check for reflexes before
starting the operational procedure. Catheters were placed in the
left femoral artery and vein, tunnelled subcutaneously to the back
of the neck and attached to a swivel, as described previously [37].
The mice were allowed to recover for 3 days before MAP was
measured by a pressure transducer (Fo¨hr Medical Instruments
GMBH, Germany) connected to an amplifier (Electronic shop,
Institute of Medical Biology, University of Southern Denmark).
The signal was digitized by an analog-to-digital converter (USB
6008, National Instruments, Austin, TX, USA), and recorded
using customized Lab View software (National Instruments). MAP
was measured for 1 hour before L-NAME infusion, and after
24 hour intravenous L-NAME infusion (8.6 mg?kg21?day21).
Administration of exogenous SP-D
The effects of exogenous SP-D treatment on body weight, food
intake, and neuropeptide gene expression profile in the hypothal-
amus were tested in male Spd2/2 and wild-type mice (8 weeks
old) by injection of native SP-D or saline either intravenously (iv)
or intracerebroventricularly (icv), or by infusion of recombinant
SP-D subcutaneously by osmotic minipumps.
For iv or icv treatments, 8 weeks old SP-D deficient and wild-
type male mice were used (n = 5–6 pr treatment group). After two-
three days of baseline measurements with free access to standard
rodent chow (Altromin 1320, Altromin, Lage, Germany) the tail
vein was injected with saline (200 ml) or 100 mg/ml human SP-D
purified from late amniotic fluid as described previously [38]. Mice
were weighed and their food intake was measured two-three days
prior to treatments in order to achieve a baseline food intake and
bodyweight. All animals had free access to standard rodent chow.
In one group of mice, single injection was followed by
measurement of neuropeptide expression 2 h later. In another
group, 3 injections were given with 2 day intervals to investigate
changes in body weight.
Icv administration was performed by placing anesthesized mice
in a stereotactic instrument (KOPF model 900 with model 5000
microinjection unit attached, and with a Hamilton syringe 75RN,
5 mL and a GA26S cannula). Anaesthesia was performed as
described for measurements of blood pressure, except that
Ketamine/Xylazine concentrations were raised to 125 mg/kg
and 25 mg/kg, respectively. Saline (2 ml) or 2 ml of human SP-D in
solution (see above) were injected at the coordinates 0.4 mm
caudal to bregma, 1 mm lateral to the midline on the right side, at
depth 2 mm [39]. In two groups of mice, neuropeptide expression
was quantified after 45 minutes and 2 hours, respectively. In a
third group, food intakes and body weights were measured for
SP-D’s Role in Metabolism
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three days after one icv injection. All experiments included sham
operated, untreated animals. The anaesthesized mice were
pinched between the toes in order to check for reflexes before
starting the operational procedure.
Before histological analysis, iv or icv treated mice were
euthanized with Pentobarbital and perfused with ice cold PBS,
the brains were removed, the hypothalami were dissected out,
placed in cryo tubes, snap frozen, and subsequently stored at
280uC.
Subcutaneous infusion of 0.82 mg/ml recombinant full length
SP-D [18] or saline was performed using Alzet osmotic minipumps
(1007D, Scanbur, Karlslunde, Denmark) placed subcutanously
under isoflurane anaesthesia in 14 weeks old male Spd2/2 mice
(n = 4 per treatment group). Body weight and food intake were
measured daily for 3 days prior to and for 6 days during infusion.
The human recombinant SP-D was measured in the terminal
blood sample using ELISA as previously described [3]. A test for
biological activity of the recombinant SP-D was performed by
detection of SP-D induced phosphorylation of p38 as previously
described [40] using human endothelial cells (HPMEC-ST1.6R
kindly provided by Dr. Ronald Unger, Institute of Pathology,
Johannes Gutenberg University, Mainz, Germany).
Sample preparation for RT-PCR
Total RNA was purified using TRIzol RNA isolation reagent
(Invitrogen Life Technologies) according to the manufacturer’s
protocol. One mg of RNA from each sample was incubated with
Moloney murine leukemia virus RT (Invitrogen Life Technolo-
gies) according to the manufacturer’s protocol, using random
hexamer primers.
PCR reaction and real-time detection of the PCR product
accumulation were performed using ABI Prism 7300 Sequence
Detection Systems (Applied Biosystems, Foster City, CA). The
qPCR was performed for POMC (Forward; TGCTTCA-
GACCTCCATAGATGTGT, Reverse; GCGAGAGGTC-
GAGTTTGCA, Probe; CTGGCTTGCATCCG), AGRP (For-
ward; GCTCCACTGAAGGGCATCA, Reverse;
TGTCTTCTTGAGGCCATTCAGA, Probe; CAGAGTTCC-
CAGGTCT) and c-fos (Forward; GCATGGGCTCTCCTGT-
CAA, Reverse; GGCACTAGAGACGGACAGATC, Probe;
ACACAGGACTTTTGC).
The ribosomal 18S rRNA (Applied Biosystems) was chosen as
endogenous control. Each reaction was performed with TaqMan
2x Universal PCR Master Mix (Applied Biosystems), primer and
TaqMan probe, and sterile milliQ water. Relative expression
values were then calculated by dividing the expression level of the
target gene by the expression level of 18S rRNA, as described
previously [41].
Stereological estimation of adipose tissue macrophages,
adipocytes and adipocyte size
Six-week-old SP-D deficient male mice and wild-type male mice
fed with 95% energy restriction were used for the experiment
(n = 3). After termination, the right gonadal, retroperitoneal, and
subcutaneous inguinal fat pads were fixed in 4% formaldehyde
and tissue sections were embedded in paraffin. Macrophages were
stained with F4/80 rat anti-mouse antibody (MCAP497, Serotech,
Oxford, UK) and counter stained with conventional Mayers
Hematoxylin and eosin stain. The numbers of adipocytes and
macrophages in three dimensions were determined using conven-
tional stereology (10 randomly selected sections from each sample
and reference tissue and counting frames 1000 mm apart [42,43]).
Adipocyte volumes were estimated using the point-sampled linear
intercepts principle [42]. All stereological procedures were
performed using an Olympus BH-2 light-microscope fitted with
an Olympus digital camera, CAST2 software (Olympus, Den-
mark), and a MW multicontrol 2000 specimen stage connected to
the computer.
Measurement of basal levels of systemic endotoxin
Eighteen weeks old male mice deficient for SP-D and wild-type
male mice fed a ground standard chow (Altromin 1320, Altromin,
Lage, Germany) were used for the experiment (n = 15–16). Mice
were fasted for the last four hours during the dark phase. Following
the light was switched on and the mice were given access to the
chow for two hours before blood samples were drawn. Sera were
obtained by retro-orbital puncture and collected using sterile glass
capillaries into glass vials, which were heated for 30 minutes at
250uC before use. Sera were subsequently diluted 1/40 in
Pyrosperse (Lonza Copenhagen Aps, Vallensbæk Strand, Den-
mark). Gram-negative bacterial endotoxin levels were measured
using the Q CL-1000 LAL-assay (Lonza Copenhagen Aps,
Vallensbæk Strand, Denmark) according to the manufacturer’s
instructions.
Statistical analysis
Comparisons between experimental group means were evalu-
ated by means of two-way ANOVA, with diet and genotype as
variables. Differences between the two genotypes in their response
to diet type were evaluated with the interaction term in the
ANOVA model, genotype*diet, when relevant. When the
genotype effect was unaffected by diet, data was presented as
least square means for the two genotypes, disregarding the type of
diet. T-test was used as post hoc test. Data used for multiple
regression modelling and matching ANOVA were normally
distributed. Residuals from the regression models were also
normally distributed as well as uniform. The Kruskal-Wallis with
Dunns post hoc test was applied for non-parametric data. P-
values,0.05 were considered significant. Statistical analyses and
graph presentations were performed using Stata Intercooled 8.0
(www.stata.com), Microsoft Excel 2008, or GraphPad Prism 5.
Results
Spd2/2 mice have elevated body mass
The body mass in 7 weeks old male Spd2/2 mice was
marginally increased compared to wild-type mice (21.660.4 vs.
20.460.3 g, p = 0.02, n= 24); however, following 18 weeks ad
libitum feeding Spd2/2 mice displayed significantly increased
body masses compared to wild-type mice assessed by single
measurements as well as by integrated areas under the curve
(AUC) (Fig. 1A). During the course of the feeding study Spd2/2
mice developed a 10% higher body mass compared to wild-type
mice, evaluated as genotype AUC. The difference in body masses
peaked at 14% at 19 weeks of age (39.661.0 vs. 34.861.0 g,
p = 0.002, n = 12). The differences in body masses between the two
genotypes were similar during high fat and low fat diets
(interaction-term, diet*genotype in the ANOVA). At 28 weeks of
age, total body protein content was increased by 4.8% (p= 0.038)
and body fat mass was increased by 27% (p,0.001) in Spd2/2
mice relative to wild-type levels (Fig. 1B). The mean masses of the
gonadal fat pads were equal in the two genotypes; however, both
the retroperitoneal and the subcutaneous fat pads were enlarged in
the Spd2/2 mice (Fig. 1C).
SP-D’s Role in Metabolism
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Body masses in Spd2/2 and wild-type mice are similar
when the energy intake is identical
Wild-type and Spd2/2 mice were submitted to restricted
feeding in order to investigate if hyperphagia contributed to the
obese phenotype. When Spd2/2 and wild-type mice were fed a
diet providing 80% of the ad libitum wild-type energy intake,
Spd2/2 mice did not increase body mass compared to wild-type
mice (Fig. 2A), and the body composition was also similar in the
two genotypes (data not shown). The same picture was seen with
mice fed a diet providing 95% of ad libitum energy intake (Fig. 2B).
The retroperitoneal, gonadal and subcutaneous inguinal fat pads
of Spd2/2 mice and wild-type mice fed a 95% restricted low fat
diet for 25 weeks were dissected and weighed. In keeping with the
lack of difference in body weight, the total masses of the three fat
pads were similar between genotypes (Fig. 2C). The retroperito-
neal deposits did not display any significant differences in masses
between the genotypes either. In contrast, the gonadal fat deposits
in Spd2/2 mice were 23% (p= 0.003) smaller, and the
subcutaneous deposits were 61% (p= 0.008) larger than those of
wild-type mice (Fig. 2C). All other organs investigated had similar
masses in the two genotypes, except for a 15% increment in kidney
size in the Spd2/2 mice (0.5260.02 vs. 0.4560.01 g, p = 0.039).
Spd2/2 mice have elevated energy consumption
Energy intake was recorded during the 18 weeks of ad libitum
feeding with isoenergetically exchanged high or low fat diets. The
daily energy intake was not constant throughout the period and
was calculated, therefore, as the slope of the accumulated energy
intake from 7–17 weeks of age and again from 18–25 weeks of age.
The energy intake of Spd2/2 mice was elevated by 3.261.3 kJ/
day relative to wild-type mice (53.760.9 vs. 50.560.8 kJ/day,
p = 0.02, n = 12) at 7–17 weeks of age, but showed no difference at
age 18 to 25 weeks (Fig. 3), and 93% of the difference in
accumulated energy intake between the genotypes was achieved
during this early experimental period. The increase in energy
intake was independent of diet composition (diet*genotype).
Gastrointestinal assimilation (digestion and absorption) of
energy was not affected by energy intake, diet, or genotype as
determined by the quotient between assimilated and gross energy
intake. Neither was metabolizable energy affected by the three
variables (data not shown).
The energy expenditure is not significantly different
between Spd2/2 and wild-type mice
Measurements of energy expenditure (EE) and substrate
oxidation were obtained in order to investigate if the observed
obese phenotype in the Spd2/2 mice could be partly explained
by alterations in EE. EE was measured after 21 weeks in mice fed
ad libitum or on an 80% restricted diet.
In line with the observation that bodymass differences between
the genotypes disappeared with energy restricted feeding, EE was
not significantly different in Spd2/2 mice compared to wild-type
mice fed ad libitum (Fig. 4A). After correction for differences in
body mass, the EE remained similar between Spd2/2 and wild-
Figure 1. Mean body masses of male mice fed ad libitum for 18
weeks. A) Spd2/2 mice had a higher body mass than their wild-type
counterparts. ANOVA of AUC showed a genotype effect (p = 0.005) and
a diet effect (p = 0.02). Diet did not influence the body mass difference
of genotypes. Data are means6 SE, n = 6. B) Carcass mass of protein, fat
and water in 28 week old mice. Protein and fat mass was increased in
Spd2/2 mice. Genotype effect, * p,0.001 and ** p= 0.038. Data are
least square means6 SE, n = 11–12. C) Mean masses of three fat pads in
28 week old mice. The gonadal fat pad mass was similar in the two
genotypes. Retroperitoneal fat, subcutaneous fat and the total of
the three pads were increased in Spd2/2 mice. Genotype effect,
* p = 0.001, ** p= 0.03, *** p = 0.047. Data are least square means +/2
SE, n = 11–12.
doi:10.1371/journal.pone.0035066.g001
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type mice when heat exchange was expressed relative to metabolic
body size (kg0.75) as well as when expressed relative to lean body
mass (data not shown). Moreover, there was no measured
disturbance in core temperature measured with a rectal probe
and thus no apparent disability to thermoregulate in the Spd2/2
mice. Spd2/2 and wild-type mice fed a diet restricted to 80% of
wild-type ad libitum energy intake likewise had identical EE (data
not shown). Oxidation of carbohydrate and fat was similar in the
Spd2/2 mice and wild-type mice, while a small difference was
seen in protein oxidation in ad libitum fed mice (Fig. 4B) as well as
in mice fed a 80% energy restricted diet (Fig. 4C). Moreover,
oxygen consumption in young mice (8 weeks old) mice of similar
body mass was not significantly different between the genotypes
(data not shown).
Fasting serum insulin, glucose and leptin are elevated in
ad libitum fed Spd2/2 mice
Fasting serum insulin, glucose, and leptin were measured after
18 weeks of high fat or low fat diet (Table 1). The fasting glucose
concentrations measured in all ad libitum fed mice at these time
points were above 10 mmol/l (180 mg/dL) indicating that they
had become hyperglycemic.
In the ad libitum fed Spd2/2 mice the same trends were
observed for measurements of glucose and insulin disregarding the
diet type although significance was not observed in all groups
(Table 1). Fasting serum insulin was increased by 48% (ns) and
82% (p= 0.008) when fed the low fat diet and high fat diet,
respectively. Fasting serum glucose was significantly elevated by
17% (p= 0.03) in low fat diet fed Spd2/2mice compared to wild-
type mice. High fasting insulin or glucose is an indicator of insulin
resistance and the insulin-glucose product was increased by 82%
(p= 0.02) and 94% (p= 0.01) in low fat diet and high fat diet fed
Spd2/2 mice, respectively (Table 1). Multiple linear regression of
the insulin-glucose product with body-mass and genotype as
independent variables revealed that the SP-D deficient genotype
influenced the proxy for insulin resistance independently of body
mass in the ad libitum fed mice (r = 0.76, body mass: p = 0.024,
genotype: p= 0.006). According to the regression model, the
genotype influenced the proxy by 13,10064,300 pg*mol/l2, while
an increase in body mass of 1 g increased the product by
1,2006500 pg*mmol/l2. Neither serum insulin nor serum glucose
Figure 2. A) Mean body mass gain in male Spd2/2 and wild-
type mice fed on a 80% energy restricted diet for 18 weeks.
ANOVA of body mass gain after 18 weeks did not show any genotype
difference. B) Mean body masses of Spd2/2 and wild-type mice fed a
95% restricted low fat diet. The body masses in Spd2/2 and wild-type
mice were equal after 25 weeks of diet treatment. C) The masses of
three fat pads from 32 week old mice fed a 95% restricted low fat diet.
The total mean mass of the three pads and the retroperitoneal pads
was equal in the two genotypes. The gonadal fat pad mass was
decreased and the subcutaneous pad was increased in Spd2/2 mice.
* p = 0.003, ** p = 0.008. Data are means + or 2 SE, n = 6.
doi:10.1371/journal.pone.0035066.g002
Figure 3. Average energy intake in Spd2/2 and wild-type
mice. At age 7–17 weeks energy intake was significantly higher in
Spd2/2 mice, but from age 18 to 25 the energy intake was identical.
Two-way anova, genotype effect, * p = 0.02. Data are least square
means + SE, n = 12.
doi:10.1371/journal.pone.0035066.g003
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was affected by SP-D deficiency in the mice fed with 80% energy
restriction.
There was great variability in measurements of serum leptin.
Fasting serum leptin was increased by 120% (p,0.05) in the ad
libitum and high fat diet fed Spd2/2 mice. There was no
significant genotype difference in leptin levels when mice were fed
with 80% energy restriction (Tab. 1). Likewise, with the 95%
energy restriction there was no significant alteration in the
systemic levels of leptin (data not shown). When analysed
separately, leptin levels showed a significant correlation to body
mass among the energy-restricted animals (R2 = 0.47, p = 0.0002),
as well as among the ad libitum fed mice (R2 = 0.23, p= 0.02)
(fig. 5).
Adiponectin levels appeared with increased levels in the energy
restricted animals, 1,4006100 pg/ml compared to
1,1006100 pg/ml in the ad libitum fed animals (p = 0.049).
Neither genotype nor diet showed any impact on adiponectin
levels (data not shown).
Mean arterial pressure in conscious mice
Mean arterial blood pressures and heart rates were measured in
8–9 months old Spd2/2 mice and wildtype mice fed a standard
diet ad libitum in order to test if SP-D deficiency would evoke
hypertension secondary to the metabolic changes. However, there
were no genotype effects in the variables. The mean arterial
pressures obtained in wild-type and Spd2/2 female mice were
97610 mmHg and 9866 mmHg, respectively. The mean arterial
pressures in the corresponding male mice were 10665 mmHg and
10466 mmHg, respectively. Infusion of L-NAME raised arterial
pressure similarly in male wild-type and Spd2/2 mice
(13.563.7% vs. 10.561.6%). Likewise there was no difference
between heart rates in the genotypes.
Administration of exogenous SP-D affected neither
central signalling nor energy intake
In order to test if treatment with exogenous SP-D could
modulate central appetite regulating pathways in the hypothala-
mus, we measured hypothalamic c-fos gene expression in response
to different treatment regimes with native human SP-D. SP-D
deficiency had no effect on the basal level of c-fos, AGRP or
POMC message in the hypothalamic tissue. Likewise, analysis of c-
fos, POMC, and AGRP gene expression after one dose icv or 3
doses over 6 days iv did not show any differences between
treatment groups.
In accordance with the above, neither intravenous injections
nor icv SP-D treatment altered energy intake in either Spd2/2
mice or wild-type controls in ad libitum fed mice. Continuous
administration by osmotic minipumps during 7 days altered
neither bodyweight development nor food intake in the period
(data not shown). At the end of the experiment, human
recombinant SP-D in the mouse circulation was measured by
ELISA. There was no detectable signal in the vehicle infusion
group, but 48620 ng/ml rSP-D was retrieved in the treated
group.
Cellular composition in adipose tissue
In order to test if there were apparent alterations in the cellular
composition in adipose tissues, three gonadal pads from each
genotype fed with 95% energy restriction were fixed for
histological examination. We used mice fed with 95% energy
restriction in order to investigate mice of different genotypes but
with identical bodyweights closely resembling the normal wildtype
weight. Infiltration of the adipose tissue with macrophages was
counted by stereology; however, no difference was seen between
body weight matched SP-D deficient mice and WT mice and
likewise there was no difference in adipocyte size between
genotypes (data not shown). Macrophage density was uncorrelated
Figure 4. Heat exchange in 28 week old Spd2/2 and wild-type
mice. A) Heat exchange per animal was not significantly different
between genotypes. B) Nutrient oxidation in ad libitum fed mice.
Protein oxidation showed a borderline genotype effect, * p = 0.049. C)
Nutrient oxidation in restricted fed mice. Protein oxidation showed a
genotype effect, * p = 0.035. Data are least square means + SE, n = 11–
12.
doi:10.1371/journal.pone.0035066.g004
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to the size of the gonadal fat pad, but it was significantly associated
to total body mass (r = 0.90, p= 0.009) as were the ratio of
macrophages to adipocytes (r = 0.97, p = 0.001) and total number
of macrophages per fat pad (r = 0.99, p,0.001).
Measurement of basal levels of systemic endotoxin
Gram negative baterial endotoxin levels were measured in mice
fed a standard chow. The blood samples were drawn during the
early hours of the light phase in order to avoid fluctuations
reported to occur late in the dark phase [34]. An approximate 2-
fold increase in the basal systemic endotoxin level was detected in
the SP-D deficient mice when compared to wild-type levels in two
independent experiments with one depicted in figure 6
(1.7761.60 EU/mL versus 0.8660.36 EU/mL, p,0.05).
Discussion
In the present study, a mouse strain carrying a disrupted gene
encoding SP-D was used to investigate the nature of SP-D
modulation of body weight and metabolism. The main results
derived from the explorations of the SP-D deficient phenotype
include hyperphagia with no apparent effect evoked by short-term
SP-D administration and no indication for involvement of
hypothalamic appetite regulation. Moreover, the SP-D deficient
phenotype was characterized by redistribution of body fat, insulin
resistance, and increased systemic bacterial endotoxin levels,
indicative of propensity for metabolic endotoxemia.
Causality between energy intake and expenditure and the obese
phenotype has previously been addressed in various genetically
modified strains including the extremely obese genotypes such as
the CH4r2/2 and the ob/ob mice [44,45,46]. Energy restricted
Spd2/2 mice did not have an increased gain of body mass, fat/
lean mass ratio, or a decreased metabolic rate. Thus, the obesity
seen in the Spd2/2 mice is primarily dependent upon an
increased energy intake and there was no apparent alteration in
gastrointestinal assimilation. Moreover, in young mice, where only
Table 1. Insulin, glucose and leptin in Spd2/2 mice and wild-type mice.
Feeding group Insulin (ng/ml) Glucose (mmol/l) Insulin*Glucose () Leptin (ng/ml)
WT LF AL 1.8060.45 10.460.50 18.2063.88 31.1766.80
Spd2/2 LF AL 2.6760.27 12.260.48* 33.0563.86* 28.4063.96
WT HF AL 1.7860.32 12.0460.64 21.0662.88 20.6761.26
Spd2/2 HF AL 3.2460.40* 12.460.51 40.9565.94* 45.5067.90*
WT LF R 0.4760.04 6.8660.16 3.2260.28 0.6760.07
Spd2/2 LF R 0.4360.09 6.0560.48 2.8360.73 1.0860.17
WT HF R 0.4960.02 7.5260.44 3.7160.29 2.0261.00
Spd2/2 HF R 0.5360.14 7.2860.48 2.9460.64 2.4060.62
Data are means 6 SE. WT =wildtype mice, Spd2/2= SP-D deficient mice, LF = low fat diet, HF = high fat diet, AL = ad libitum, R = 80% energy restricted.
*p,0.05.
doi:10.1371/journal.pone.0035066.t001
Figure 5. Linear association between ln(leptin) levels and
mouse body weights.Mice from different feeding groups show linear
relation between systemic leptin levels and body weights (Spd2/2,
wild type, high fat, low fat) when fed with 80% energy restriction or ad
libitum.
doi:10.1371/journal.pone.0035066.g005
Figure 6. Serum endotoxin levels. Serum endotoxin levels were
significantly increased in 16 SP-D deficient mice compared to 15 wild-
type mice during the light phase period and fed a standard chow ad
libitum. * p,0.05. Data were logaritmically transformed to obtain
normality before testing. Data are means + standard deviations.
doi:10.1371/journal.pone.0035066.g006
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small and insignificant differences in body mass had developed,
oxygen consumption did not differ significantly. In contrast,
hyperphagia seemed to predominate in young mice as increased
energy intake was evident in Spd2/2 mice from 6–7 weeks of
age, but normalized in .18 week old mice.
We chose to examine hypothalamic POMC and AGRP, due to
their major function as part of the melanocortin system involving
in appetite regulation [47,48,49,50]. In our experiments no effect
of the short term SP-D treatment on hypothalamic POMC and
AGRP gene expression could be measured after peripheral and/or
central administration. This type of negative observation is
reported previously e.g. in fasted GM-CSF deficient and
hyperphagic rats [48]. Likewise analysis of c-fos induction after
icv or iv treatment did not show any difference between treatment
groups, neither within the genotypes receiving different com-
pounds nor between the genotypes treated with the same
compound. The lack of effect of short term exogenous SP-D on
c-fos expression in hypothalamus, however, leaves open the
possibility that the primary action of SP-D on energy balance is
located in the extrahypothalamic area. Expression of SP-D in
human brain tissue has been reported [6] and immunostaining has
localized SP-D to human brain endothelium (GL Sorensen and U
Holmskov, unpublished) [7]. On the basis of the performed
experiments, we cannot rule out that alternative routes of
administration or prolonged treatment periods with exogenous
SP-D would affect the energy intake.
Given that pulmonary derangement per se may be involved in
the development of the metabolic syndrome, mouse strains with
pulmonary phenotypes may be predisposed for an obese or
diabetic phenotype. SP-D deficient mice and Granulocyte
Macrophage-Colony Stimulating Factor (GM-CSF) deficient mice
may represent such strains. These strains are previously reported
with resemblance between emphysematic phenotypes, although
the resulting pathology may be evoked through distinct mecha-
nisms [51]. The GM-CSF deficient mice also represent a model of
mild obesity. GM-CSF, however, is reported to act through
receptor mediated CNS signalling [48]. The emphysematic
Spd2/2 phenotype was not quantified in this study, but as the
mice neither had altered energy expenditure from possible failure
to thrive nor emphysema related cachexia, this aspect of the SP-D
deficient phenotype was apparently not involved in the induction
of the metabolic phenotype.
Development of the metabolic syndrome in humans is thought
promoted by high fat diet. To investigate the effect of fat on the
metabolic syndrome in Spd2/2 mice, we fed the mice a diet with
an increased proportion of fat. The low and high fat diets used in
our study were isoenergetically exchanged to evaluate the effect on
body mass development without differences in protein, vitamins
and minerals to influence the results. Although the body mass of
mice on a high fat diet was elevated by 9% compared to mice on a
low fat diet the genotype dependent increase in body weight, was
not significantly different between the different diets and thus did
not determine the major outcomes of the study.
Previously low serum SP-D has been demonstrated to be
associated with BMI in human studies [8,9,10,52]. In the setting of
obesity, the ability of the adipose tissue to produce antiinflamma-
tory mediators such as adiponectin decreases, whereas proin-
flammatory cytokines such as IL-6, TNF-a, and acute phase
reactants, and other innate immune mediators increase [53,54,55].
SP-D deviates somewhat from this picture and is found to be
decreased not only in subjects with obesity, but also type 2 diabetes
and is negatively associated with fasting serum glucose. Moreover,
SP-D is found positively associated with insulin sensitivity,
suggesting that decreased SP-D expression could be behind the
association of lung function with impaired insulin actions in type II
diabetes [8]. In contrast, a recent study has demonstrated that high
systemic SP-D is predictive for cardiovascular mortality [11]
underscoring that the interpretation about causality behind the
clinical associations must come from animal studies. The data
presented here support that a lack of SP-D induces hyperphagia,
and fat deposits, and reduces insulin sensitivity. On the other
hand, previous data indicated that SP-D induced atherosclerosis
[26]. Thus, the complex clinical associations are so far supported
by a similarly complex SP-D deficient phenotype.
We further observed that Spd2/2 mice had increased
subcutaneous fat and decrements in retroperitoneal and gonadal
fat fad sizes according to feeding regime. The SP-D dependent
redistribution of fat deposits may be particularly interesting in the
context of atheromata formation with visceral fat being associated
to disease [56,57,58]. In the present investigations adipocyte
number, size, or the fraction of adipose tissue macrophages did not
indicate that SP-D deficiency would affect the inflammatory state
of the fat tissue. Moreover, no alterations in mean arterial pressure
or in endothelial function assessed by the responsiveness towards
L-name infusion were found to potentially explain the role of SP-D
in atheroma formation.
A possible role for the gut microbiota in obesity and additional
aspects of the metabolic syndrome was recently proposed [59]. In
both humans and mice, the development of obesity was dependent
on the relative abundance of specific bacterial phyla in the gut
[60,61,62], and transfer of the gut microbiota from obese mice to
germ-free wild-type mice led to an increase in fat mass in the
recipients indicating increased capacity for host energy harvest
induced by the microbiome [63]. A recently appreciated
characteristic of obesity is an aberrant intestinal microbiota
composition in obese individuals or animals, which appears to
be linked to the obese state itself and susceptible to dietary
modulation. However, whether this aberrant microbiota compo-
sition plays an etiological role in obesity or is a consequence of the
diet in obesity remains to be determined as reviewed by Conterno
L., et al., 2011 [64].
Lately the involvement of innate immune receptors was
documented. Toll-like receptor 5 (TLR5) is expressed in the gut
mucosa and it was demonstrated that TLR52/2 mice exhibited
hyperphagia and developed metabolic disturbances, including
insulin resistance, and increased adiposity. The changes correlated
with changes in the composition of the gut microbiota [65].
Likewise, mice with loss-of-function mutation in TLR4 are
protected against the development of diet-induced obesity and
insulin resistance [66,67]. It is further demonstrated that high fat
diets could induce metabolic endotoxemia, which can dysregulate
the inflammatory tone and trigger body weight gain and diabetes
[34].
Whereas SP-D is present in the human circulation in relatively
high levels [52] there is no or very low measurable SP-D in the
normal mouse blood, but in this species, age or pulmonary
inflammation will induce serum SP-D to measurable levels [2,68].
SP-D is expressed in the gut epithelium [6]. SP-D may thus
contribute to scavenging or neutralizing systemic endotoxin
derived from gut microbiota at these sites. SP-D has been
described to bind to a variety of endotoxin subtypes and to interact
directly with the TLR4/CD14 complex affecting endotoxin
signalling [19,69,70]. In this context, systemic endotoxin levels
were tested in SP-D deficient mice and found significantly
increased. A potentially altered composition of gut microbiata in
the SP-D deficient mice remains to be explored as a consequence
of prolonged SP-D treatment and of obesity per se. Nevertheless,
the present data indicate that intestinal or systemic SP-D
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neutralization of metabolic endotoxemia may contribute to the
hyperphagic and metabolic phenotype in the SP-D deficient mice.
In conclusion, we have shown that SP-D modulates energy
intake, and that hyperphagia is the primary cause of the obese
phenotype of SP-D deficient mice. Moreover, we have found that
Spd2/2 mice have altered fat distribution, a characteristic not
dependent on hyperphagia, that increased insulin resistance and
hyperleptinaemia were developed secondary to hyperphagia in
Spd2/2 mice, and that low-grade endotoxemia may contribute
to the metabolic phenotype. The results are in line with association
between low serum SP-D and BMI and type II diabetes in clinical
stuides. The present experiments did not provide definitive
mechanistic insight into the hyperphagic phenotype of the KO
mice. However, SP-D mediated clearance or neutralization of
endotoxin or SP-D dependent signaling in relation to hormonal
control of energy intake may directly drive hyperphagia and other
mechanisms of the metabolic syndrome. Further studies are
needed in order to clarify the mode of action of SP-D in this
context.
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